Brokerages Expect Neon Therapeutics Inc (NASDAQ:NTGN) to Announce -$0.62 EPS

Wall Street brokerages expect Neon Therapeutics Inc (NASDAQ:NTGN) to report earnings per share of ($0.62) for the current quarter, according to Zacks. Zero analysts have made estimates for Neon Therapeutics’ earnings. The highest EPS estimate is ($0.43) and the lowest is ($0.77). Neon Therapeutics posted earnings of ($0.84) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 26.2%. The business is expected to announce its next earnings report on Monday, March 9th.

On average, analysts expect that Neon Therapeutics will report full year earnings of ($2.55) per share for the current fiscal year, with EPS estimates ranging from ($3.01) to ($1.71). For the next year, analysts expect that the firm will report earnings of ($2.21) per share, with EPS estimates ranging from ($3.86) to ($1.13). Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that follow Neon Therapeutics.

Neon Therapeutics (NASDAQ:NTGN) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.04).

A number of brokerages have recently weighed in on NTGN. Zacks Investment Research raised shares of Neon Therapeutics from a “hold” rating to a “buy” rating and set a $2.00 price target for the company in a research note on Saturday, October 12th. Bank of America lowered shares of Neon Therapeutics from a “buy” rating to a “neutral” rating in a research note on Wednesday. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price target on shares of Neon Therapeutics in a research note on Monday, November 11th. ValuEngine raised shares of Neon Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Finally, Robert W. Baird began coverage on shares of Neon Therapeutics in a research note on Thursday, July 25th. They issued an “outperform” rating and a $15.00 price target for the company. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $13.00.

Several large investors have recently modified their holdings of the company. Marshall Wace North America L.P. acquired a new stake in Neon Therapeutics during the first quarter valued at approximately $49,000. Bank of New York Mellon Corp lifted its stake in Neon Therapeutics by 112.1% during the second quarter. Bank of New York Mellon Corp now owns 71,443 shares of the company’s stock valued at $339,000 after purchasing an additional 37,755 shares during the last quarter. Northern Trust Corp lifted its stake in Neon Therapeutics by 8.5% during the second quarter. Northern Trust Corp now owns 166,467 shares of the company’s stock valued at $789,000 after purchasing an additional 12,971 shares during the last quarter. Westfield Capital Management Co. LP acquired a new stake in Neon Therapeutics during the second quarter valued at approximately $149,000. Finally, BlackRock Inc. lifted its stake in Neon Therapeutics by 11.6% during the second quarter. BlackRock Inc. now owns 765,850 shares of the company’s stock valued at $3,631,000 after purchasing an additional 79,729 shares during the last quarter. 67.91% of the stock is owned by institutional investors.

NTGN stock traded down $0.15 during trading on Monday, reaching $1.50. The stock had a trading volume of 141,800 shares, compared to its average volume of 121,770. Neon Therapeutics has a 1-year low of $1.47 and a 1-year high of $7.51. The company has a current ratio of 4.59, a quick ratio of 6.13 and a debt-to-equity ratio of 0.15. The company has a market capitalization of $46.76 million, a P/E ratio of -0.27 and a beta of 1.59. The firm has a fifty day moving average price of $1.95 and a 200 day moving average price of $3.50.

Neon Therapeutics Company Profile

Neon Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer.

See Also: Why do earnings reports matter?

Get a free copy of the Zacks research report on Neon Therapeutics (NTGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Neon Therapeutics (NASDAQ:NTGN)

Receive News & Ratings for Neon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.